Related Articles
Top Stories
May 25 2012 13:58
The costs of the first phase of the Gauteng Freeway Improvement Project have increased significantly to almost R90bn, according to a report.
May 24 2012 17:31
The Reserve Bank will maintain current interest rates, and a considerable reduction in the local petrol price is anticipated, says governor Gill Marcus.
May 25 2012 11:36
The JSE has identified and stopped "incorrect" trades from one of its members, and will reverse the trades and lower the session's total value after the close.
London - GlaxoSmithKline has taken a 19% stake in Africa's biggest generic drugmaker, Aspen Pharmacare, after completing a strategic collaboration with the South African group, the companies said on Tuesday.
British-based Glaxo had originally said it would have a 16% holding when the deal was announced in May, but it has since bought additional Aspen shares to increase its interest.
The asset-swap deal expands Glaxo's emerging market presence - a key objective for chief executive Andrew Witty - and cements an existing relationship between the two businesses.
Aspen has issued 68.5 million new shares to Glaxo in exchange for Glaxo's manufacturing plant in Bad Oldesloe, Germany, and eight specialist medicines.
Taken together with Aspen shares bought by Glaxo between signing and closing, this issue takes Glaxo's holding in Aspen to a total of 81.7 million shares, equivalent to 19%.
Abbas Hussain, Glaxo's head of emerging markets, will be appointed to Aspen's board as a non-executive director from December 7.
- Reuters